Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

EVX-01

Vaccine (Peptide vaccine) · Immune activation, directed at patient-specific tumor neoantigens · developed by Evaxion Biotech

Phase 2 Most advanced trial (none active)
EVAX Developer
1 Registered trials

What is EVX-01?

EVX-01 is a personalized liposomal peptide vaccine made of patient-specific neoepitopes derived from tumor-associated antigens. The neoepitopes are designed to induce cytotoxic T-lymphocyte responses against tumor cells expressing these antigens. It is being studied in combination with standard of care for unresectable or stage IV melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Peptide vaccine)
Targets
patient-specific tumor neoantigens (antigen)
Mechanism
Immune activation, directed at patient-specific tumor neoantigens
Therapy area
Oncology
Developer
Evaxion Biotech A/S (EVAX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05309421 Phase 2 Melanoma Stage IV Completed EVAX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Melanoma Stage IVUnresectable Melanoma

More from Evaxion Biotech

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the EVAX page.

Follow EVAX, the company behind EVX-01

See EVAX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EVAX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.